What happened
Two WHO safety advisory committees issued a joint statement on rapidly increasing use of GLP-1 receptor agonists, particularly for weight loss.
What we know
The statement highlights risks from obtaining medicines outside approved indications, regulated channels and professional supervision. It also encourages reporting adverse events through national pharmacovigilance systems.
What it does not say
It does not conclude that the whole class is unsafe or replace national product information. WHO's recommendation for adult obesity is conditional and sits within continuing care.
Why it matters
Safety depends partly on provenance, monitoring and responsible communication. Personal experiences may raise signals but cannot prove causation or replace official pharmacovigilance.